Chronic Obstructive Pulmonary Disease (COPD) is a progressive, debilitating, chronic respiratory disease that affects 600 million people worldwide and is responsible for 3 million deaths worldwide each year. Given the recent advances in artificial intelligence (AI) and the availability of large datasets from both the public and private sectors, our project applies AI to analyze large-scale medical datasets and develops tools capable of performing accurate diagnosis, severity assessment, and prognosis of COPD.
Chronic Obstructive Pulmonary Disease (COPD) is a common illness that affects millions of Canadians, yet there are no effective therapies to treat it. Genes play a role in COPD development, and our proposal aims at identifying those genes in lung tissue that cause the disease. The Providence Airway Centre is very committed at helping COPD patients in Canada and worldwide. The proposed studies with Drs.
Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder of the lung, and one that affects 2.6 million Canadians and 380 million people worldwide. Although the disease affects a large population worldwide the therapies used for treatment remain imprecise. With the lack of disease modifying therapies there is a pressing need to discover novel targets to promote new therapeutic discoveries and ultimately improve the care and health outcomes of patients with COPD.
Chronic Obstructive Pulmonary Diseases (COPD) is a lung disease that cause a lot of suffering to the Canadian population. To accelerate the drug discovery process, an old blood pressure lowering medication was tested to block the progression of COPD. A patient study showed that the old medication did provide some protective effect to the lung airways of COPD patients. However, we have found that this old medication does not slow down COPD by lowering blood pressure, but rather by acting on a new, unknown target.
COPD is a progressive inflammatory airway disease characterized by persistent and progressive airway inflammation. It is a major cause of global morbidity and mortality and is predicted to become the third leading cause of death by 2020. Biomarkers may be useful for diagnosing disease considering that the usually used lung function measures have poor correlation with both symptoms and other measures of disease progression. However, the relationship between biomarkers and COPD is still elusive.
Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder of the lung, which is characterized by shortness of breath and progressive loss in lung function, and one that affects 2.6 million Canadians and 380 million people worldwide. The current therapies are very imprecise and none modifies disease progression or mortality. Therefore, there is a pressing need to discover new therapeutic targets that may be important molecular drivers of airways disease in COPD.
Organs-on-chips are miniature devices mimicking aspects of human organ functions. Their main purpose is to serve as an alternative to animals as a testing ground for drugs, pollutants and toxins to see their effects on organs. The lung-on-a-chip device, which is the focus of this research, has been used to demonstrate how air-born nanosized particles can irritate the lung tissues and cause inflammation. It can also help us in designing sprays and aerosols for carrying drugs into the lungs.
COPD is a common inflammatory lung condition that is characterized by airflow limitation and symptoms of cough and shortness of breath. Globally, it affects 384 million people and is responsible for ~4-7% of all deaths. Longitudinal genome-wide association studies (GWAS) are needed to unravel the molecular determinants of dynamic quantitative traits underlying COPD, such as decline in lung function over time.
Analysis of longitudinal GWAS to find biomarker of lung function decline was unsuccessful in the past. None of the discovered biomarkers were replicable.
Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder of the lung, and one that affects 2.6 million Canadians and 380 million people worldwide. The current therapies are very imprecise and none modifies disease progression or mortality. There is a pressing need to discover novel targets to enable precision health, promote new therapeutic discoveries, and ultimately improve the care and health outcomes of patients with COPD. However, this process is hindered by the use of outdated cell culture systems and animal models.
The continuum of HIV care is highly complex. It includes prevention, testing, patient care, treatment, and support services. This project will help Providence Health Care utilise its limited resources to provide the best treatment and care for people living with HIV in Vancouver. Care for HIV patients includes antiretroviral therapy, treatment of co-morbidities, monitoring clinical markers of disease progression (CD4 count and viral load), and support services to ensure treatment adherence and retention in care.